Trial Profile
A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers With Response and Resistance
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 13 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 01 Sep 2016 Status changed from not yet recruiting to recruiting.